Development of IG-100 (dasatinib), an inhibitor of multiple signaling kinases in a Phase 2a study which will be the first time that dasatinib is administered to NS and NSML pediatric patients with diagnosed HCM. IGIA was founded in 2017 by a team of leading scientists with a combined century of experience in drug development, who are committed to the development of pharmaceutical products for the treatment of orphan indications or small population indications with an unmet medical need.
Services
IGIA Pharmaceuticals, Inc (IGIA), a pharmaceutical company based outside of Cincinnati, Ohio, specializing in the development of pharmaceutical products for the treatment of orphan indications or small population indications with an unmet medical need. IGIA has developed novel formulation technology that facilitates clinical studies in infants and children.
This on-market tyrosine kinase inhibitor (TKI) demonstrates better toxicological parameters than Rapamycin. Palliative effects on HCM and cardiac function were observed at dosages far below those employed in cancer therapy. This implies that a regiment of low-dose Dasatinib may improve HCM and cardiac function in NS, and reverse HCM in NSML (80% of cases).
The IGIA team are experienced drug development professionals. Lois Rosenberger, PhD is the President and owner of LBR Regulatory-Clinical Consulting Services (LBR) and Acting CEO of IGIA Pharmaceutics. LBR is a niche Contract Research Organization (CRO) that will be used by IGIA Pharmaceuticals to administer the Phase 2 drug development program for dasatinib.
Reviews
Be the first to review Igia Pharmaceuticals.
Write a Review
